Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
44,162,869
-
Number of holders
-
49
-
Total 13F shares, excl. options
-
27,187,955
-
Shares change
-
-3,081,731
-
Total reported value, excl. options
-
$21,995,839
-
Value change
-
-$2,401,932
-
Number of buys
-
20
-
Number of sells
-
-35
-
Price
-
$0.8094
Significant Holders of Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) as of Q2 2025
64 filings reported holding PRLD - Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share as of Q2 2025.
Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) has 49 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 27,187,955 shares
of 44,162,869 outstanding shares and own 62% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (10,909,256 shares), BAKER BROS. ADVISORS LP (10,123,824 shares), VANGUARD GROUP INC (932,570 shares), PRICE T ROWE ASSOCIATES INC /MD/ (927,608 shares), RENAISSANCE TECHNOLOGIES LLC (581,800 shares), ACADIAN ASSET MANAGEMENT LLC (540,565 shares), BlackRock, Inc. (432,559 shares), MORGAN STANLEY (284,382 shares), MILLENNIUM MANAGEMENT LLC (248,423 shares), and TWO SIGMA ADVISERS, LP (225,000 shares).
This table shows the top 49 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.